Monoclonal Antibody Development Platform
Monoclonal antibodies (mAb) are highly uniform antibodies produced by a single B cell clone and only target a specific antigenic epitope. Our company employs talented and highly trained scientists who focus on every aspect of therapeutic antibody development and can carry out entire monoclonal antibody development. Our team can customize monoclonal antibody development for your rare disease therapy research project according to your specific requirements.
Methods of Monoclonal Antibody Development
Monoclonal antibodies are often produced by hybridoma technology. Based on cell fusion technology, hybridoma antibody technology fuses sensitizing B cells with the ability to secrete specific antibodies and myeloma cells with the ability to reproduce indefinitely to form B cell hybridoma. The immune response was first triggered by immunizing the mice with the desired antigen, and then their blood was screened for antibodies. Isolated antibody-producing splenocytes were fused with myeloma cells to produce hybridoma cells capable of unlimited growth. After screening, the selected leads were used to generate chimeric or humanized antibodies.
In addition to hybridoma technology, phage display, transgenic mouse immunization, and single B cell technology can also be used for the production of monoclonal antibodies.
Monoclonal Antibody for Rare Diseases
Currently, a variety of monoclonal antibodies have been approved for clinical, and more are undergoing clinical trials. Antibody drugs have the characteristics of high specificity and few adverse reactions. Therefore, the development of monoclonal antibodies provides more possibilities for rare disease therapy research and development. Here are some examples of monoclonal antibodies being used to treat rare diseases.
|Crohn's disease / Psoriatic arthritis
|Blocks interleukin IL-12 and IL-23
|Targets phosphoprotein CD20 on B lymphocytes
Over the years, our company has been committed to the construction and improvement of antibody development platforms. We can provide hybridoma technology, phage display, transgenic mouse immunization, and single B cell technology for the development of monoclonal antibodies, as well as provide PK study and drug safety evaluation of monoclonal antibodies. The monoclonal antibody development services we can provide include but are not limited to:
- Mouse mAb Production
- Rabbit mAb Production
- Recombinant Ab Production
- Hybridoma Sequencing
- Anti-idiotype Ab Production
- Phospho Specific Ab Production
As an integrated CRO, we have the capabilities and resources to provide a one-stop, personalized, and customized service to ensure that we can quickly respond to the changing needs of your rare disease research projects.
With extensive experience and advanced platforms, our company is able to provide proteins, peptides, nucleotides and other macromolecules as antigens.
Choose an appropriate protocol to inject the immunogen into the host animal to generate an immune response and ensure the best immunoreactivity / quantity of immunogen ratio, and detection methods are developed for each test bleed.
Spleen cells were mixed with myeloma cells and cultured in HAT selective medium in the presence of polyethylene glycol (PEG) for several weeks, and the remaining animals were kept in the animal facility for future use.
Providing hybridoma screening, isolate positive hybridomas, and using ELISA method to detect cell growth stability and antibody specificity. Providing you with cryopreservation service for up to 10 positive hybridomas.
We continue to isolate polyclonal hybridomas and provide you with the ELISA test results of the supernatant. In order to obtain stable antibodies, we can further expand the cells.
Providing a variety of purification methods including protein A/G purification, IgG purification, IgY purification, low endotoxin purification and affinity purification to purify monoclonal antibodies.
With a research team with extensive expertise in rare disease therapy research and development, our company is confident in providing customers with monoclonal antibody development. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Lu, Ruei-Min, et al. "Development of therapeutic antibodies for the treatment of diseases." Journal of biomedical science 27.1 (2020): 1-30.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.